Article Details
Retrieved on: 2024-11-06 23:30:24
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Chardan raised the firm's price target on Arbutus Biopharma (ABUS) to $4.50 from $4 and keeps a Buy rating on the shares after its Q3 results.
Article found on: www.tipranks.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here